MCID: SCK001
MIFTS: 38

Sick Building Syndrome malady

Category: Respiratory diseases

Aliases & Classifications for Sick Building Syndrome

About this section

Aliases & Descriptions for Sick Building Syndrome:

Name: Sick Building Syndrome 11 2 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:2710
SNOMED-CT62 19076009
MeSH39 D018877

Summaries for Sick Building Syndrome

About this section
CDC:2 Indoor environmental quality (IEQ) refers to the quality of a building’s environment in relation to the health and wellbeing of those who occupy space within it. IEQ is determined by many factors, including lighting, air quality, and damp conditions. Workers are often concerned that they have symptoms or health conditions from exposures to contaminants in the buildings where they work. One reason for this concern is that their symptoms often get better when they are not in the building. While research has shown that some respiratory symptoms and illnesses can be associated with damp buildings, it is still unclear what measurements of indoor contaminants show that workers are at risk for disease. In most instances where a worker and his or her physician suspect that the building environment is causing a specific health condition, the information available from medical tests and tests of the environment is not sufficient to establish which contaminants are responsible. Despite uncertainty about what to measure and how to interpret what is measured, research shows that building-related symptoms are associated with building characteristics, including dampness, cleanliness, and ventilation characteristics.

MalaCards based summary: Sick Building Syndrome is related to cleft lip palate-tetraphocomelia and neurogenic arthropathy. An important gene associated with Sick Building Syndrome is PNPLA6 (Patatin Like Phospholipase Domain Containing 6), and among its related pathways are Adipocytokine signaling pathway and Endochondral Ossification. Affiliated tissues include testes, eye and endothelial, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and neoplasm.

Disease Ontology:11 An extrinsic allergic alveolitis that is characterized by a set of symptoms such as headache, fatigue, eye irritation, and breathing difficulties that affect workers in modern airtight office buildings. The disease is caused by indoor pollutants (as formaldehyde fumes, particulate matter, or microorganisms), and the symptoms tend to disappear when affected individuals leave the building.

Wikipedia:71 Sick building syndrome (SBS) a medical condition where people in a building suffer from symptoms of... more...

Related Diseases for Sick Building Syndrome

About this section

Graphical network of the top 20 diseases related to Sick Building Syndrome:



Diseases related to sick building syndrome

Symptoms & Phenotypes for Sick Building Syndrome

About this section

GenomeRNAi Phenotypes related to Sick Building Syndrome according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-1929.0LEP, LRP6, POMC

MGI Mouse Phenotypes related to Sick Building Syndrome according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.0LEP, MMP9, POMC, VEGFA
2MP:00053718.7LEP, LRP6, MMP9, VEGFA
3MP:00053708.5LEP, LRP6, POMC, VEGFA
4MP:00053858.3LEP, MMP9, PNPLA6, POMC, VEGFA
5MP:00053678.3LEP, LRP6, MMP9, POMC, VEGFA
6MP:00053767.9LEP, LRP6, MMP9, PNPLA6, POMC, VEGFA
7MP:00053847.8LEP, LRP6, MMP9, PNPLA6, POMC, VEGFA
8MP:00053787.8LEP, LRP6, MMP9, PNPLA6, POMC, VEGFA
9MP:00107717.7LEP, LRP6, MMP9, PNPLA6, POMC, VEGFA
10MP:00053867.1ITM2B, LEP, LRP6, MMP9, PNPLA6, POMC
11MP:00036316.9ITM2B, LEP, LRP6, MMP9, PNPLA6, POMC

Drugs & Therapeutics for Sick Building Syndrome

About this section

Drugs for Sick Building Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DopamineapprovedPhase 3383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
2
SerotoninPhase 3362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
3Neurotransmitter AgentsPhase 318340
4Psychotropic DrugsPhase 36430
5Serotonin 5-HT2 Receptor AntagonistsPhase 3225
6Tranquilizing AgentsPhase 34265
7Adrenergic AgentsPhase 35352
8Serotonin AgentsPhase 33156
9
Lurasidone hydrochloridePhase 358367514-87-2213046
Synonyms:
367514-88-3
441351-20-8
D04820
Lurasidone HCl
Lurasidone hydrochloride
 
Lurasidone hydrochloride (USAN)
MK-3756
N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3-bicyclo(2.2.1)heptanedicarboximide
SM 13496
SM-13496
SMP-13496
10Serotonin AntagonistsPhase 31409
11Adrenergic AntagonistsPhase 31573
12Adrenergic alpha-AntagonistsPhase 3739
13Dopamine D2 Receptor AntagonistsPhase 3333
14Antipsychotic AgentsPhase 32401
15Central Nervous System DepressantsPhase 313403
16Dopamine AntagonistsPhase 31093
17Dopamine AgentsPhase 33836
18
Dexamethasoneapproved, investigational, vet_approvedPhase 1217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
19
LenograstimapprovedPhase 11220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
20Dexamethasone acetatePhase 121711177-87-3
21Dexamethasone 21-phosphatePhase 12171
22BB 1101Phase 12171
23Adjuvants, ImmunologicPhase 12554
24
Ritonavirapproved, investigational883155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
25
Tipranavirapproved, investigational73174484-41-465027
Synonyms:
174484-41-4
1d4y
2o4l
2o4n
2o4p
AC1L22FH
AC1Q4JPW
Aptivus
Aptivus (Boehringer Ingelheim)
Aptivus (TN)
Aptivus(TM)
CHEMBL222559
CID65027
 
D08605
DB00932
MolPort-003-850-561
N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
PNU 140690
PNU-140690
PNU-140690E
TPV
Tipranavir
Tipranavir (INN)
U 140690
U-140690
UNII-ZZT404XD09
tipranavir
26Antiviral Agents9967
27Anti-Retroviral Agents3296
28Anti-HIV Agents3162
29Anti-Infective Agents22062
30Immunoglobulins6394
31Antibodies6394
32Autoantibodies130

Interventional clinical trials:

idNameStatusNCT IDPhase
1A Twelve Week, Open Label Extension Study in Patients With SchizophreniaCompletedNCT01566162Phase 3
2PEARL Schizophrenia MaintenanceCompletedNCT01435928Phase 3
3HIV Prevention With the Mentally IllCompletedNCT00643305Phase 2
4Improved Methods of Cell Selection for Bone Marrow Transplant AlternativesRecruitingNCT00001529Phase 1
5Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV InfectionApproved for marketingNCT00062660
6Texting to Improve Adherence in HIV+ With Bipolar DisorderCompletedNCT02090634
7Literacy-Adapted Psychosocial Treatments for Chronic Pain --- "Learning About Mastering/My Pain"CompletedNCT01967342
8An Integrated Program for the Treatment of First Episode of PsychosisActive, not recruitingNCT01321177
9Neuropsychological Outcomes of Internationally-Adopted Children Who Are Perinatally-Infected With Human Immunodeficiency VirusEnrolling by invitationNCT03100331
10Serum Auto-Antibodies in Neurological DiseasesEnrolling by invitationNCT00704626

Search NIH Clinical Center for Sick Building Syndrome


Cochrane evidence based reviews: sick building syndrome

Genetic Tests for Sick Building Syndrome

About this section

Anatomical Context for Sick Building Syndrome

About this section

MalaCards organs/tissues related to Sick Building Syndrome:

36
Testes, Eye, Endothelial, Colon

Publications for Sick Building Syndrome

About this section

Articles related to Sick Building Syndrome:

(show top 50)    (show all 205)
idTitleAuthorsYear
1
Cognitive therapy in sick building syndrome: Myths, believes or evidence. (26654822)
2016
2
Outdoor air pollution, meteorological conditions and indoor factors in dwellings in relation to sick building syndrome (SBS) among adults in China. (27101454)
2016
3
Endotoxin, ergosterol, muramic acid and fungal DNA in dust from schools in Johor Bahru, Malaysia--Associations with rhinitis and sick building syndrome (SBS) in junior high school students. (26745297)
2016
4
Reply to Letter to the Editor: Cognitive therapy in Sick Building Syndrome: Myths, beliefs or evidence. (26684264)
2016
5
Sick building syndrome (SBS) among office workers in a Malaysian university - Associations with atopy, fractional exhaled nitric oxide (FeNO) and the office environment. (26225741)
2015
6
Association of Sick Building Syndrome with Indoor Air Parameters. (26221153)
2015
7
Assessment of sick building syndrome and its associating factors among nurses in the educational hospitals of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. (25716375)
2015
8
Effect of Traffic Exposure on Sick Building Syndrome Symptoms among Parents/Grandparents of Preschool Children in Beijing, China. (26086248)
2015
9
Sick Building Syndrome Among Junior High School Students in Japan in Relation to the Home and School Environment. (26383200)
2015
10
Social determinants of the sick building syndrome: exploring the interrelated effects of social position and psychosocial situation. (25424591)
2014
11
Effects of ventilation rate per person and per floor area on perceived air quality, sick building syndrome symptoms, and decision-making. (25142723)
2014
12
Allostatic load model associated with indoor environmental quality and sick building syndrome among office workers. (24759685)
2014
13
A Longitudinal Study of Sick Building Syndrome (SBS) among Pupils in Relation to SO2, NO2, O3 and PM10 in Schools in China. (25398002)
2014
14
Odors and sensations of humidity and dryness in relation to sick building syndrome and home environment in Chongqing, China. (23991107)
2013
15
Airborne molds and bacteria, microbial volatile organic compounds (MVOC), plasticizers and formaldehyde in dwellings in three North European cities in relation to sick building syndrome (SBS). (23280302)
2013
16
Association of sick building syndrome with neuropathy target esterase (NTE) activity in Japanese. (23418070)
2013
17
Sick building syndrome by indoor air pollution in Dalian, China. (23579877)
2013
18
Prevalence and risk factors of sick building syndrome among office workers. (23963091)
2013
19
Sick building syndrome (SBS) and sick house syndrome (SHS) in relation to psychosocial stress at work in the Swedish workforce. (23143072)
2013
20
A longitudinal study of aldehydes and volatile organic compounds associated with subjective symptoms related to sick building syndrome in new dwellings in Japan. (22265600)
2012
21
Dampness and moulds in workplace buildings: associations with incidence and remission of sick building syndrome (SBS) and biomarkers of inflammation in a 10 year follow-up study. (22634552)
2012
22
The new model of sick building syndrome. (22350575)
2012
23
Office workers' sick building syndrome and indoor carbon dioxide concentrations. (22530709)
2012
24
The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants. (21188456)
2011
25
A longitudinal study of sick building syndrome among pupils in relation to microbial components in dust in schools in China. (21943723)
2011
26
Sick Building Syndrome and autoimmunity. (21300685)
2011
27
Relationships between mite allergen levels, mold concentrations, and sick building syndrome symptoms in newly built dwellings in Japan. (21198888)
2011
28
The prevalence and incidence of sick building syndrome in Chinese pupils in relation to the school environment: a two-year follow-up study. (21615503)
2011
29
The possible role of fungal contamination in sick building syndrome. (21196335)
2011
30
Sick building syndrome in a general hospital and the risks for pregnant workers. (21458809)
2011
31
Sick building syndrome in relation to domestic exposure in Sweden--a cohort study from 1991 to 2001. (19850651)
2010
32
Dampness, food habits, and sick building syndrome symptoms in elementary school pupils. (21432556)
2010
33
Relationship between indoor chemical concentrations and subjective symptoms associated with sick building syndrome in newly built houses in Japan. (19902238)
2010
34
Association study between sick building syndrome and polymorphisms of seven human detoxification genes in the Japanese. (21787601)
2010
35
Relationship between sick building syndrome and indoor environmental factors in newly built Japanese dwellings. (19205722)
2009
36
An update on sick building syndrome. (19532093)
2009
37
Association of neuroticism with sick building syndrome, quality of life and psychomotor performance. (19662780)
2009
38
Quantitative relationship of sick building syndrome symptoms with ventilation rates. (19207289)
2009
39
A longitudinal study of environmental risk factors for subjective symptoms associated with sick building syndrome in new dwellings. (19608217)
2009
40
Sick Building Syndrome: is mould the cause? (19255924)
2009
41
Molds, mycotoxins, and sick building syndrome. (19854820)
2009
42
Relation of dampness to sick building syndrome in Japanese public apartment houses. (19568865)
2009
43
Indoor environment in dwellings, asthma, allergies, and sick building syndrome in the Swedish population: a longitudinal cohort study from 1989 to 1997. (19618200)
2009
44
Do you have sick building syndrome? (18648309)
2008
45
Medical and social prognoses of non-specific building-related symptoms (Sick Building Syndrome): a follow-up study of patients previously referred to hospital. (17924130)
2008
46
Sick building syndrome in relation to air exchange rate, CO(2), room temperature and relative air humidity in university computer classrooms: an experimental study. (18246367)
2008
47
The sick building syndrome. (20040980)
2008
48
Symptom definitions for SBS (sick building syndrome) in residential dwellings. (17574916)
2008
49
Oxidative stress associated with indoor air pollution and sick building syndrome-related symptoms among office workers in Taiwan. (17127643)
2007
50
Office work exposures [corrected] and respiratory and sick building syndrome symptoms. (17339295)
2007

Variations for Sick Building Syndrome

About this section

Expression for genes affiliated with Sick Building Syndrome

About this section
Search GEO for disease gene expression data for Sick Building Syndrome.

Pathways for genes affiliated with Sick Building Syndrome

About this section

GO Terms for genes affiliated with Sick Building Syndrome

About this section

Cellular components related to Sick Building Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1secretory granuleGO:00301419.4POMC, VEGFA
2extracellular spaceGO:00056158.2ITM2B, LEP, MMP9, POMC, VEGFA
3extracellular regionGO:00055767.8ITM2B, LEP, LRP6, MMP9, POMC, VEGFA

Biological processes related to Sick Building Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1macrophage differentiationGO:00302259.9MMP9, VEGFA
2dopaminergic neuron differentiationGO:00715429.9LRP6, VEGFA
3positive regulation of p38MAPK cascadeGO:19007459.8LEP, VEGFA
4regulation of blood pressureGO:00082179.5LEP, POMC

Molecular functions related to Sick Building Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor bindingGO:00051029.0LEP, LRP6, POMC

Sources for Sick Building Syndrome

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet